Investor Relations

Introduction

Current treatment options for opioid and other forms of addiction do not work for most people. What’s missing is the ability to fast track the withdrawal process. Ibogaine – a molecule found in Tabernanthe iboga and other plants – offers the opportunity for a rapid detox. In combination with an effective therapeutic setting, ibogaine offers the opportunity to live free from addiction. Our goal is to provide safe, effective and affordable ibogaine treatment internationally this decade.

Why go public now? To enable public participation in an ibogaine-focused company incorporating: 

Milestones

.01

Clinical Trials Application to Commence

.02

Conventional Detox Clinics in Operation in 2021

.03

Phase 2 Clinical Trials begin in 2022

.04

 Phase 3 Clinical Trials begin in Q3 2022

 Our balance of medical expertise, clinic operations, and capital markets relationships puts us on a path for success.

Financials

Financials will be available once they are filed and we are a fully reporting publicly traded company.

We have completed a Subscription Receipt Qualifying Transaction, we aim to be publicly trading in September 2021.

Being publicly owned allows everyone to be a part of the solution and enables us to obtain required funding for clinical trials in Canada and overseas

Investor Presentation

Board of Directors

Chief Ian Campbell

Chief Ian Campbell, MBA

Chairman

Dr. Alberta Sola

Dr. Alberta Sola, Ph.D

CoFounder & Director

Marilyn Mauritz

Marilyn Mauritz

Director

Robert Turner, MBA

Robert Turner, MBA

Director

Connect with Us

OUR WHY

TEAM

UNIVERSAL IBOGAINE
NEWS